Passage BIO, Inc. (PASG) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Passage BIO, Inc. on July 29, 2025, covering events occurring on July 28, 2025. The Company is an emerging growth company incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol "PASG".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a corporate governance and listing status event.
Material Changes
- Regaining Nasdaq Compliance: On July 28, 2025, the Company received confirmation from the Nasdaq Listing Qualifications staff that it has regained compliance with Nasdaq Listing Rule 5450(a)(1).
- Stock Price Recovery: As of July 28, 2025, the closing bid price of the Company's common stock had been at least $1.00 per share for at least 10 consecutive business days.
- Resolution of Delisting Notice: This determination closes the listing matter initiated on August 1, 2024, when the Company was notified of non-compliance due to its stock price falling below $1.00 per share for 30 consecutive business days.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks or contingencies. The primary risk addressed was the potential delisting from the Nasdaq Capital Market, which has been resolved as of the report date.
Key Facts for Investor Verification
- Verify the current trading status of PASG on the Nasdaq Capital Market to confirm continued listing.
- Confirm the closing bid price of the stock remains at or above $1.00 per share to maintain compliance with Nasdaq Listing Rule 5450(a)(1).
- Note that this filing resolves a specific compliance issue from August 2024 but does not provide updated financial performance data.